文献速递妇科

血清鳞状细胞癌抗原与宫颈鳞状细胞癌患者复发及生存的相关性:系统综述与荟萃分析

The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2018-03-29

该系统综述与荟萃分析纳入61项研究,评估治疗前后血清鳞状细胞癌抗原(SCC-Ag)与宫颈鳞状细胞癌复发和死亡风险的关联。治疗前高SCC-Ag者复发风险RR为2.44(95%CI:1.91,3.13),死亡风险RR为3.66(95%CI:2.24,5.98)。作者认为该标志物可能有助于监测疾病进展。

要点

  • 治疗前高SCC-Ag与复发风险升高相关,合并RR为2.44(95%CI:1.91,3.13)。
  • 治疗前高SCC-Ag与死亡风险升高相关,合并RR为3.66(95%CI:2.24,5.98)。
  • 治疗后SCC-Ag与复发和死亡也呈类似趋势,合并RR分别为3.91和见原文。

核心结论

  • 血清SCC-Ag与新诊断宫颈癌的复发和死亡持续相关,该标志物可能有助于监测宫颈癌患者的疾病进展。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和Scopus数据库至2016年6月29日,共纳入61项评估SCC-Ag对宫颈癌患者复发和死亡影响的研究。
  • 数据提取由两名评价员独立完成,合并效应量包括风险比(RR)、风险比(HR)和未标准化均数差(USMD)。

主要发现

  • 治疗前高vs低血清SCC-Ag与复发的合并RR为2.44(95%CI:1.91,3.13),合并HR为2.23(95%CI:2.03,2.45),合并USMD为-7.7(95%CI:-31.7,16.4)。
  • 治疗后高vs低血清SCC-Ag与复发的合并RR为3.91(95%CI:2.96,5.16),合并HR为3.14(95%CI:1.29,7.65),合并USMD为3.2(95%CI:-10.6,17.0)。
  • 治疗前高vs低血清SCC-Ag与死亡的合并RR为3.66(95%CI:2.24,5.98),合并HR为2.50(95%CI:1.85,3.37),合并USMD为7.10(95%CI:4.26,9.94)。
  • 治疗后血清SCC-Ag对死亡的影响也反映类似趋势。

临床怎么用

  • 作者认为血清SCC-Ag可能有助于监测宫颈癌患者的疾病进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this systematic review and meta-analysis was to pool association effects of serum squamous cell carcinoma antigen (SCC-Ag) on recurrence and mortality in mainly squamous cell cervical cancer patients. METHODS: MEDLINE and Scopus databases were searched up to June 29, 2016. Studies assessing effects of SCC-Ag on recurrence and death in cervical cancer patients were included. Data extraction was independently performed by two reviewers. A meta-analysis was applied for pooling the effects (i.e., risk ratio (RR), hazard ratio (HR), and unstandardized mean difference (USMD)) of SCC-Ag measured before and after treatment on recurrence and death. RESULTS: A total of 61 studies were included. For pretreatment SCC-Ag and recurrence, the pooled RR, HR, and USMD for high versus low serum SCC-Ag were 2.44(95% CI: 1.91, 3.13), 2.23(95% CI: 2.03, 2.45), -7.7(95% CI: -31.7, 16.4), respectively. The corresponding effects for the posttreatment period were 3.91(95% CI: 2.96, 5.16), 3.14(95% CI: 1.29, 7.65), and 3.2(95% CI: -10.6, 17.0), respectively. In addition, patients with high level of pretreatment serum SCC-Ag were also at a higher risk for death than patients with low serum SCC-Ag with a pooled RR of 3.66(95% CI: 2.24, 5.98), pooled HR of 2.50(95% CI: 1.85, 3.37), and pooled USMD of 7.10(95% CI: 4.26, 9.94). The posttreatment serum SCC-Ag effects also reflected a similar trend. CONCLUSIONS: The serum SCC-Ag was consistently associated with recurrence and mortality of newly diagnosed cervical cancer. This marker may be useful in monitoring disease progression in cervical cancer patients. Prospero registration number is: CRD42016044024.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Charakorn C, Thadanipon K, Chaijindaratana S, et al. The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis. Gynecol Oncol. 2018. PMID: 29606483. doi:10.1016/j.ygyno.2018.03.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。